Responses to checkpoint inhibition in metastatic triple negative breast cancer driven by divergent myeloid phenotypes

Our findings highlight CD33⁺ cell phenotype as a key determinant of response to chemo-immunotherapy, which can be assessed from peripheral blood. This offers a valuable tool in the context of metastatic TNBC, in which tissue sampling is often challenging.